[Form 4] QUEST DIAGNOSTICS INC Insider Trading Activity

Rhea-AI Filing Summary

Quest Diagnostics senior executive Mark E. Delaney, SVP & Chief Commercial Officer, reported stock option exercises and a share sale in Quest Diagnostics Inc. common stock. On 11/18/2025, he exercised 7,846 stock options at an exercise price of $144.47 per share and 100 stock options at $143.33 per share, acquiring the same number of Quest Diagnostics shares. On the same date, he sold 7,946 shares of common stock at a price of $187.35 per share. Following these transactions, he directly owned 7,530 shares of Quest Diagnostics common stock. The filing notes that the exercise and sale were carried out under a pre-arranged Rule 10b5-1 sales plan adopted by the reporting person.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

DELANEY MARK E

(Last) (First) (Middle)

500 PLAZA DRIVE

C/O QUEST DIAGNOSTICS INC

(Street)

SECAUCUS NJ 07094

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	SVP & Chief Commercial Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/18/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/18/2025		M(1)		7,846	A	$144.47	15,376	D
Common Stock	11/18/2025		M(1)		100	A	$143.33	15,476	D
Common Stock	11/18/2025		S(1)		7,946	D	$187.35	7,530	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Non-Qualifed Stock Option (right to buy)	$144.47	11/18/2025		M(1)			7,846	(2)	03/21/2032	Common Stock	7,846	$144.47	0	D
Non-Qualifed Stock Option (right to buy)	$143.33	11/18/2025		M(1)			100	(2)	02/23/2033	Common Stock	100	$143.33	7,484	D

Explanation of Responses:

1. This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

2. The options vest in three equal annual installments beginning on the first annual anniversary of the grant date.

Remarks:

	Sean D. Mersten, Attorney in Fact for Mark E. Delaney	11/20/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did DGX executive Mark E. Delaney report?

Mark E. Delaney, SVP & Chief Commercial Officer of Quest Diagnostics Inc. (DGX), reported exercising stock options and selling common shares in the company on 11/18/2025.

How many Quest Diagnostics (DGX) options did the executive exercise?

He exercised 7,846 non-qualified stock options at an exercise price of $144.47 per share and 100 non-qualified stock options at $143.33 per share, receiving the same number of Quest Diagnostics common shares.

How many Quest Diagnostics (DGX) shares were sold and at what price?

On 11/18/2025, he sold 7,946 shares of Quest Diagnostics common stock at a price of $187.35 per share.

How many Quest Diagnostics (DGX) shares does the insider own after the transactions?

After the reported transactions, he directly beneficially owned 7,530 shares of Quest Diagnostics common stock.

Were the DGX insider transactions made under a Rule 10b5-1 plan?

Yes. The filing states that the exercise and sale were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.

What are the terms of the DGX stock options mentioned in the filing?

The non-qualified stock options have exercise prices of $144.47 and $143.33 and are scheduled to vest in three equal annual installments beginning on the first anniversary of the grant date, with expiration dates of 03/21/2032 and 02/23/2033, respectively.